Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
In an open-label, dose-escalation, German Phase I trial in 12 epithelial cancer patients, IGN311 was well tolerated with a serum half-life of >20 days. Patients received 50, 100 or 200 mg IV IGN311 on...
